Exelixis (EXEL +3.6%) says it's licensed its PI3K-delta research and development program to...
Exelixis (EXEL +3.6%) says it's licensed its PI3K-delta research and development program to Merck (MRK +0.2%) for $12M plus an additional $239M in combined milestone and royalty payments. The sale will allow the company to focus its energies on developing its lead compound cabozantinib, a potential treatment for cancer.
From other sites
at CNBC.com (Dec 8, 2014)
at CNBC.com (Sep 29, 2014)
at CNBC.com (Sep 2, 2014)
at CNBC.com (Aug 6, 2014)
at CNBC.com (Jul 28, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs